Noah Cook, Ira Driscoll, Julian M Gaitán, Matthew Glittenberg, Tobey J Betthauser, Cynthia M Carlsson, Sterling C Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Dena B Dubal, Ozioma C Okonkwo
{"title":"在认知功能未受损的 KLOTHO KL-VS 杂合子中,淀粉样蛋白-β阳性率较低。","authors":"Noah Cook, Ira Driscoll, Julian M Gaitán, Matthew Glittenberg, Tobey J Betthauser, Cynthia M Carlsson, Sterling C Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Dena B Dubal, Ozioma C Okonkwo","doi":"10.1177/13872877241289785","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Klotho, encoded by the <i>KLOTHO</i> gene, is an anti-aging and neuroprotective protein. <i>KLOTHO</i> KL-VS heterozygosity (KL-VS<sub>HET</sub>) is hypothesized to be protective against the accumulation of Alzheimer's disease (AD) neuropathological hallmarks (amyloid-β (Aβ) and tau).</p><p><strong>Objective: </strong>We examine whether being positive for Aβ (A+) or tau (T+), or A/T joint status [positive for Aβ (A + T-), tau (A-T+), both (A + T+) or neither (A-T-)] vary by KL-VS and whether serum klotho protein levels vary based on A+, T+, or A/T status in a cohort enriched for AD risk.</p><p><strong>Methods: </strong>The sample consisted of 704 cognitively unimpaired, late middle-aged, and older adults; Mean<sub>Age</sub>(SD) = 64.9(8.3). Serum klotho was available for a sub-sample of 396 participants; Mean<sub>Age</sub>(SD) = 66.8(7.4). Covariate-adjusted logistic regression examined whether A + or T+, and multinomial regression examined whether A/T status, vary by KL-VS genotype. Covariate-adjusted linear regression examined whether serum klotho levels differ based on A+, T+, or A/T status.</p><p><strong>Results: </strong>A+ prevalence was lower in KL-VS<sub>HET</sub> (<i>p </i>= 0.05), with no differences in T + prevalence (<i>p </i>= 0.52). KL-VS<sub>HET</sub> also had marginally lower odds of being A + T- (<i>p </i>= 0.07). Serum klotho levels did not differ based on A+, T+, or A/T status (all <i>ps </i>≥ 0.40).</p><p><strong>Conclusions: </strong>KL-VS<sub>HET</sub> is associated with lower odds of being positive for Aβ, regardless of whether one is also positive for tau. Conversely, the likelihood of being tau positive did not differ based on KL-VS genotype. Our findings add to the growing <i>KLOTHO</i> literature and suggests the need for further research focused on understanding the mechanisms underlying KL-VS-related putative resilience to AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"480-490"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amyloid-β positivity is less prevalent in cognitively unimpaired <i>KLOTHO</i> KL-VS heterozygotes.\",\"authors\":\"Noah Cook, Ira Driscoll, Julian M Gaitán, Matthew Glittenberg, Tobey J Betthauser, Cynthia M Carlsson, Sterling C Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Dena B Dubal, Ozioma C Okonkwo\",\"doi\":\"10.1177/13872877241289785\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Klotho, encoded by the <i>KLOTHO</i> gene, is an anti-aging and neuroprotective protein. <i>KLOTHO</i> KL-VS heterozygosity (KL-VS<sub>HET</sub>) is hypothesized to be protective against the accumulation of Alzheimer's disease (AD) neuropathological hallmarks (amyloid-β (Aβ) and tau).</p><p><strong>Objective: </strong>We examine whether being positive for Aβ (A+) or tau (T+), or A/T joint status [positive for Aβ (A + T-), tau (A-T+), both (A + T+) or neither (A-T-)] vary by KL-VS and whether serum klotho protein levels vary based on A+, T+, or A/T status in a cohort enriched for AD risk.</p><p><strong>Methods: </strong>The sample consisted of 704 cognitively unimpaired, late middle-aged, and older adults; Mean<sub>Age</sub>(SD) = 64.9(8.3). Serum klotho was available for a sub-sample of 396 participants; Mean<sub>Age</sub>(SD) = 66.8(7.4). Covariate-adjusted logistic regression examined whether A + or T+, and multinomial regression examined whether A/T status, vary by KL-VS genotype. Covariate-adjusted linear regression examined whether serum klotho levels differ based on A+, T+, or A/T status.</p><p><strong>Results: </strong>A+ prevalence was lower in KL-VS<sub>HET</sub> (<i>p </i>= 0.05), with no differences in T + prevalence (<i>p </i>= 0.52). KL-VS<sub>HET</sub> also had marginally lower odds of being A + T- (<i>p </i>= 0.07). Serum klotho levels did not differ based on A+, T+, or A/T status (all <i>ps </i>≥ 0.40).</p><p><strong>Conclusions: </strong>KL-VS<sub>HET</sub> is associated with lower odds of being positive for Aβ, regardless of whether one is also positive for tau. Conversely, the likelihood of being tau positive did not differ based on KL-VS genotype. Our findings add to the growing <i>KLOTHO</i> literature and suggests the need for further research focused on understanding the mechanisms underlying KL-VS-related putative resilience to AD.</p>\",\"PeriodicalId\":14929,\"journal\":{\"name\":\"Journal of Alzheimer's Disease\",\"volume\":\" \",\"pages\":\"480-490\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13872877241289785\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877241289785","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes.
Background: Klotho, encoded by the KLOTHO gene, is an anti-aging and neuroprotective protein. KLOTHO KL-VS heterozygosity (KL-VSHET) is hypothesized to be protective against the accumulation of Alzheimer's disease (AD) neuropathological hallmarks (amyloid-β (Aβ) and tau).
Objective: We examine whether being positive for Aβ (A+) or tau (T+), or A/T joint status [positive for Aβ (A + T-), tau (A-T+), both (A + T+) or neither (A-T-)] vary by KL-VS and whether serum klotho protein levels vary based on A+, T+, or A/T status in a cohort enriched for AD risk.
Methods: The sample consisted of 704 cognitively unimpaired, late middle-aged, and older adults; MeanAge(SD) = 64.9(8.3). Serum klotho was available for a sub-sample of 396 participants; MeanAge(SD) = 66.8(7.4). Covariate-adjusted logistic regression examined whether A + or T+, and multinomial regression examined whether A/T status, vary by KL-VS genotype. Covariate-adjusted linear regression examined whether serum klotho levels differ based on A+, T+, or A/T status.
Results: A+ prevalence was lower in KL-VSHET (p = 0.05), with no differences in T + prevalence (p = 0.52). KL-VSHET also had marginally lower odds of being A + T- (p = 0.07). Serum klotho levels did not differ based on A+, T+, or A/T status (all ps ≥ 0.40).
Conclusions: KL-VSHET is associated with lower odds of being positive for Aβ, regardless of whether one is also positive for tau. Conversely, the likelihood of being tau positive did not differ based on KL-VS genotype. Our findings add to the growing KLOTHO literature and suggests the need for further research focused on understanding the mechanisms underlying KL-VS-related putative resilience to AD.
期刊介绍:
The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.